Assertio Holdings (ASRT) Receives Reiterated Buy Rating with $3.50 Price Target

Assertio Holdings (ASRT) received a reiterated Buy rating from HC Wainwright & Co. with a $3.50 price target. The analyst's forecast maintains the company's market confidence and stable price projections. The average target price for ASRT is $2.80, with an upside of 320.55% from the current price of $0.67. The average brokerage recommendation is 2.0, indicating "Outperform" status. The estimated GF Value for ASRT in one year is $1.04, suggesting a 56.2% upside from the current price.

Assertio Holdings Inc. (NASDAQ: ASRT) has received a reiterated Buy rating from HC Wainwright & Co. with a price target of $3.50. The analyst's forecast maintains the company's market confidence and stable price projections. The average target price for ASRT is $2.80, with an upside of 320.55% from the current price of $0.67. The average brokerage recommendation is 2.0, indicating "Outperform" status. The estimated GF Value for ASRT in one year is $1.04, suggesting a 56.2% upside from the current price.

On May 13, 2025, HC Wainwright & Co. reiterated its bullish stance on ASRT, maintaining its "Buy" rating and price target of $3.50. The analyst, Douglas Tsao, expressed confidence in the company's future performance despite current market conditions [2].

The company reported a loss of $13.5 million in the first quarter of 2025, compared to a loss of $4.5 million in the prior year. Net product sales for the quarter came in at $26 million, slightly ahead of expectations. Gross margin improved to 70% from 65% a year ago, while SG&A expenses increased to $22 million from $18.5 million [3].

Despite the earnings miss, analysts remain optimistic about ASRT's prospects. The company has strengthened its payer coverage, starting with Cigna, and expects further expansion in the second half of the year. The revised Simpazan promotional strategy has proven effective, with a 6.5% year-over-year increase in total prescriptions [3].

Institutional investors continue to show interest in ASRT. Several hedge funds, including Nantahala Capital Management LLC and Geode Capital Management LLC, have increased their holdings in the company. As of the first quarter of 2025, institutional investors owned 48.96% of ASRT's shares [1].

The stock has been volatile, trading up $0.03 during mid-day trading on May 12, 2025, reaching $0.67. The company's 50-day simple moving average is $0.65, and its 200-day simple moving average is $0.80. ASRT has a market capitalization of $63.77 million, a P/E ratio of -0.91, and a beta of 0.32 [1].

References

[1] https://www.marketbeat.com/instant-alerts/assertio-nasdaqasrt-downgraded-to-hold-rating-by-stocknewscom-2025-05-12/
[2] https://www.gurufocus.com/news/2858068/xene-hc-wainwright-reiterates-buy-rating-for-xenon-pharmaceuticals-xene-stock-news
[3] https://www.gurufocus.com/news/2857297/assertio-asrt-price-target-cut-by-alliance-global-partners-following-q1-report-asrt-stock-news